Last reviewed · How we verify
Alinia (NITAZOXANIDE)
Alinia works by inhibiting the Anoctamin-1 ion channel, disrupting the parasite's ability to maintain its cellular environment.
At a glance
| Generic name | NITAZOXANIDE |
|---|---|
| Sponsor | Romark |
| Drug class | Antiprotozoal [EPC] |
| Target | Anoctamin-1 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2002 |
Mechanism of action
Nitazoxanide is an antiprotozoal see Microbiology (12.4)].
Approved indications
- Giardiasis
- Infection by Cryptosporidium
Common side effects
- abdominal pain
- headache
- chromaturia
- nausea
- diarrhea
- gastroesophageal reflux disease
- dizziness
- dyspnea
- rash
- urticaria
Key clinical trials
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Nitazoxanide for Treatment of Cryptosporidium in Children (PHASE3)
- Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers (PHASE1)
- AGILE (Early Phase Platform Trial for COVID-19) (PHASE1,PHASE2)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children (NA)
- Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |